Royalty Pharma (RPRX)
Health Care · Biopharmaceutical royalty acquisition and life sciences funding
The largest buyer of biopharmaceutical royalties, generating cash from top-line sales of leading therapies while funding innovation across the industry.
What Royalty Pharma does
Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. The company acquires royalty interests entitling it to payments based directly on top-line sales of commercial biopharmaceutical products, operating a portfolio of over 35 commercial products and 20 development-stage candidates. It generates revenue primarily through Portfolio Receipts (royalty receipts and milestone payments) from its carefully curated portfolio of high-quality therapies. The company acts as a capital allocator in life sciences, leveraging deep industry expertise and proprietary analytics to identify and acquire royalty opportunities at attractive risk-adjusted returns.
Themes: ["biopharmaceutical royalties","life sciences capital allocation","pharmaceutical innovation funding","royalty-based cash flows","drug development financing"]
Fundamentals
- Price$57.96 as of 2026-07-09 close
- Market cap$33.4B as of 2026-07-10
- 1-year return+61.6% as of 2026-07-09 close
- P/E40.33 as of 2026-07-10
- Net margin+33.9% as of 2026-07-10
- ROE+12.7% as of 2026-07-10
- Debt / equity1.30 as of 2026-07-10
- Revenue growth (YoY)+7.8% as of 2026-07-10
- Revenue CAGR (3y)+2.1% SEC XBRL
- Beta0.44 as of 2026-07-10
Dividend: yield +1.6%; 5-year non-decreasing per-share dividend streak (SEC XBRL).
Key risks (from latest filing)
["Royalty revenue depends on sales of underlying biopharmaceutical products, which are subject to pricing pressures, clinical trial failures, regulatory delays, competitive pressures, and loss of patent protection—all of which could reduce or eliminate royalty payments","The royalty market may not grow at historical rates, limiting availability of acquisition targets at targeted rates of capital deployment and potentially constraining business growth","Development-stage product candidates in the portfolio may fail to reach the market or underperform expectations, negatively impacting future returns on invested capital and internal rates of return"]
Competitors & peers
- Ares Management (specialty finance / royalty competitors)
- KKR (life sciences / healthcare investment platforms)
- Blackstone (alternative asset management with healthcare royalty capabilities)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.